Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov

医学 内科学 危险系数 肿瘤科 临床试验 无进展生存期 贝伐单抗 免疫疗法 荟萃分析 置信区间 癌症 总体生存率 化疗
作者
Aidan Lyanzhiang Tan,Raphaël Porcher,Perrine Créquit,Philippe Ravaud,Agnès Dechartres
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (15): 1686-1694 被引量:55
标识
DOI:10.1200/jco.2016.71.2109
摘要

Purpose We aimed to compare treatment effect sizes between overall survival (OS) and progression-free survival (PFS) in trials of US Food and Drug Administration–approved oncology immunotherapy drugs with results posted at ClinicalTrials.gov . Methods We searched ClinicalTrials.gov for phase II to IV cancer trials of Food and Drug Administration–approved immunotherapy drugs and selected those reporting results for both OS and PFS. For each trial, we extracted the hazard ratios (HRs) with 95% CIs for both outcomes and evaluated the differences by a ratio of HRs (rHRs): the HR for PFS to that for OS. We performed a random effects meta-analysis across trials to obtain a summary rHR. We also evaluated surrogacy of PFS for OS by the coefficient of determination and the surrogacy threshold effect, the minimal value of HR for PFS to predict a non-null effect on OS. Results We identified 51 trials assessing 14 drugs across 15 conditions. Treatment effect sizes were 17% greater, on average, with PFS than with OS (rHR, 0.83; 95% CI, 0.79 to 0.88; I 2 = 34.4%; P = .01; τ 2 = 0.0129). Nearly one half of the trials (n = 23, 45%) showed statistically significant benefits for PFS but not for OS. Differences were great for trials of obinutuzumab (rHR, 0.21; 95% CI, 0.08 to 0.54), bevacizumab (rHR, 0.75; 95% CI, 0.67 to 0.84), and rituximab (rHR, 0.79; 95% CI, 0.64 to 0.98). The coefficient of determination was 38% and the surrogacy threshold effect was 0.50. Conclusion Treatment effect sizes in trials of immunotherapy drugs were greater for PFS than for OS, with important differences for some drugs, which is consistent with surrogacy metrics. Caution must be taken when interpreting PFS in the absence of OS data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晓凡完成签到,获得积分10
刚刚
科研通AI5应助linkman采纳,获得10
刚刚
今后应助linkman采纳,获得30
刚刚
土豪的铭完成签到,获得积分10
刚刚
威武的皮卡丘完成签到,获得积分10
刚刚
ljx完成签到 ,获得积分10
1秒前
biomds完成签到,获得积分10
1秒前
李雪松完成签到 ,获得积分10
1秒前
西早完成签到 ,获得积分10
1秒前
善学以致用应助Qyyy采纳,获得10
1秒前
落后的夜阑完成签到,获得积分10
1秒前
热心市民小红花应助AIT采纳,获得10
1秒前
西瓜完成签到,获得积分10
1秒前
zcy完成签到 ,获得积分10
1秒前
塔塔饼完成签到,获得积分10
1秒前
乌漆嘛黑完成签到,获得积分10
2秒前
Shuey完成签到,获得积分10
2秒前
研友_VZG7GZ应助spencer采纳,获得10
2秒前
我在高维宇宙完成签到,获得积分10
2秒前
NexusExplorer应助biog12采纳,获得20
3秒前
酸奶烤着吃完成签到,获得积分10
3秒前
明理的问兰完成签到,获得积分10
3秒前
暴躁的马里奥完成签到,获得积分10
3秒前
lilili发布了新的文献求助30
3秒前
科研喵发布了新的文献求助10
3秒前
柠檬精翠翠完成签到 ,获得积分10
3秒前
blue2021发布了新的文献求助10
4秒前
拉长的问晴完成签到,获得积分10
4秒前
刘城发布了新的文献求助10
4秒前
Rosie完成签到,获得积分10
4秒前
土木搬砖法律完成签到,获得积分10
4秒前
oneko完成签到,获得积分10
4秒前
4秒前
Antidote完成签到,获得积分10
5秒前
xueshudog完成签到,获得积分10
5秒前
高兴的灰狼完成签到,获得积分10
5秒前
AAAsun完成签到,获得积分10
5秒前
5秒前
zhu完成签到,获得积分10
5秒前
6秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968719
求助须知:如何正确求助?哪些是违规求助? 3513608
关于积分的说明 11168681
捐赠科研通 3248960
什么是DOI,文献DOI怎么找? 1794573
邀请新用户注册赠送积分活动 875194
科研通“疑难数据库(出版商)”最低求助积分说明 804716